Document ID: chunk:federal_register_of_legislation:F2024L01521:clause:1_29
Version: federal_register_of_legislation:F2024L01521
Segment Type: clause
Provision Reference: sch 1 cl 29
Character Range: 17587–18801

29  Schedule 1 (table)
After:
Olmesartan  Tablet containing olmesartan medoxomil 40 mg  Oral  OLMERTAN  (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
                                                                          (b) after 31 December 2023—3.5 months stock by reference to usual demand

insert:
Olmesartan with amlodipine  Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)   Oral  APO-OLMESARTAN/AMLODIPINE 20/5   4 months stock by reference to usual demand of both Olmesartan/Amlodipine 20/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 20/5 mg added together
Olmesartan with amlodipine  Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)  Oral  APO-OLMESARTAN/AMLODIPINE 40/10  4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/10 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/10 added together
Olmesartan with amlodipine  Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)   Oral  APO-OLMESARTAN/AMLODIPINE 40/5   4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/5 mg added together